Eli Lilly’s GLP-1 Dominance: Beyond the Blockbuster Numbers
Eli Lilly’s blockbuster quarter with Zepbound and Mounjaro signals more than just financial success. The pharmaceutical giant faces critical challenges in scaling production and defending market share against intensifying competition.